VQ Biomedical develops a minimally-invasive catheter designed to deliver supplemental oxygen directly into the bloodstream for hospitalized patients experiencing respiratory failure. This intravascular oxygenation technology provides gas exchange independent of the injured lungs, allowing them time to heal without relying on mechanical ventilation or external ECMO circuits. The system offers a lower risk profile for patients and reduces operational complexity and cost for healthcare providers.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with severe respiratory failure or those undergoing cardiac surgeries often require supplemental oxygenation. Current methods like mechanical ventilation and VV-ECMO can be invasive, carry significant risks, and may further damage fragile lungs.
Solution
VQ Biomedical is developing a minimally-invasive intravascular oxygenation catheter designed to deliver supplemental oxygen directly into the bloodstream of hospitalized patients. This technology aims to provide gas exchange independent of the lungs, allowing them to rest and recover. Unlike VV-ECMO, the catheter oxygenates blood directly without requiring blood to be pumped outside the body. The catheter is designed to be easy to use, operated by a single control, and aims to reduce staffing requirements compared to existing methods. By delivering oxygen directly into the bloodstream, the device intends to lower the risk profile associated with traditional oxygenation methods.
Target Audience
The primary target audience includes hospitals and medical professionals treating patients with respiratory failure or those undergoing cardiac surgeries.
Features
- Minimally-invasive catheter design for direct intravascular oxygen delivery
- Gas exchange independent of the lungs, promoting lung rest and recovery
- Simplified operation with a single control for ease of use
- Lower risk profile compared to ECMO or mechanical ventilation